Clinical Trial Update: Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel plus cetuximab in head and neck squamous cell carcinoma after failure of first-line checkpoint inhibitors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Medical University of Vienna | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED